Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Clinical Profile of Documented Diabetic Peripheral Neuropathy by GLP-1-Based Medication Status: A Cross-Sectional Study
Medicina (Kaunas, Lithuania), 2026;62(9)
Incretin signaling suppresses high glucose-induced β-cell hypoxia through a cAMP/PKA-dependent mechanism
Biochemical and biophysical research communications, 2026;838:154627
When weight-loss drugs reduce drinking: glucagon-like peptide-1 receptor agonists as phenotype-enriched harm-reduction therapy for alcohol use disorder
Annals of medicine and surgery (2012), 2026;88(10):6240-6243
Glucagon-like receptor-1 agonists and impotence: A meta-analysis
World journal of methodology, 2026;16(3):119385
Pancreatic-liver crosstalk, novel molecular mediators, and 2025 therapeutic breakthroughs
World journal of methodology, 2026;16(3):118728
Economic evaluations of antiobesity medications: A systematic literature review
British journal of clinical pharmacology, 2026
Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP
Diabetes, obesity & metabolism, 2026
Cargo-aware design of dissolving microneedles: an FEA-guided rational framework reveals distinct delivery mechanisms for small and large molecules
International journal of pharmaceutics, 2026;:127394
Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study
Diabetes research and clinical practice, 2026;:113573
Dementia progression with GLP-1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target-trial emulation study
Alzheimer's & dementia (New York, N. Y.), 2026;12(3):e70315
GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework
Journal of clinical medicine, 2026;15(18)
GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection
International journal of molecular sciences, 2026;27(18)
From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD
International journal of molecular sciences, 2026;27(18)
Reprogramming NAD+ homeostasis and FOXO3a-Nrf2 signaling mitigates bleomycin-driven pulmonary fibrosis
Toxicology and applied pharmacology, 2026;:118045
Changes in Abdominal Adiposity and Associations With Metabolic Health Markers Following Tirzepatide in Japanese Participants With Obesity Disease: Results From the SURMOUNT-J Study
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity: comment
Internal and emergency medicine, 2026
Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome
Medical sciences (Basel, Switzerland), 2026;14(5)
Dangers of Injectable Peptides and Other Unregulated “Biohacking” Drugs
Missouri medicine;123(4):337-343
Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model
PloS one, 2026;21(9):e0358225
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment
The Annals of pharmacotherapy, 2026;:10600280261486055